Kornimate/medical-research-clean huggingface dataset:
study of the vascular compartment and hypercoagulability during coronavirus infection covid-19

Conditions: COVID-19

Summary: coronavirus covid-19 is an emerging virus also called severe acute respiratory syndrome coronavirus 2 (sars-cov-2). eighty percent of patients are poor or asymptomatic. however, there are major respiratory complications for some patients, requiring intensive care hospitalization and possibly leading to death in 5% of cases. one of the hypotheses put forward is that much of the pathophysiology is due to endothelial dysfunction associated with disseminated intravascular coagulation. the covid-19 pathology could induce coagulation impairment as observed during sepsis. an increase in d-dimer levels during covid-19 disease is itself associated with excess mortality. while d-dimers are highly sensitive, they are not specific for clotting activity. they may be increased in many other circumstances, particularly in inflammation. on the other hand, the infection stimulates the release of extracellular vesicles. these vesicles, of multiple cellular origin, are an actor of vascular homeostasis, and participate in the state of hyperactivation of coagulation. they have a major role in the prothrombotic state and the development of coagulopathy associated with sepsis. the aim of our monocentric prospective study would be to study early and more specific markers of hypercoagulability and markers of routine endothelial dysfunction, as soon as the patient is hospitalized, in order to predict the risk of hospitalization in intensive care.


Eligibility criteria:
inclusion criteria: * any adult patient admitted to rouen university hospital for documented sars-cov-2 infection (pcr test or ct scan) * patient who accept to participate to research after reading the information note * patient affiliated with social security exclusion criteria: * patient under protective guardianship or curatorship

Keywords: hemostasis
role of laparoscopy in penetrating anterior abdominal wall injuries

Conditions: Evaluate Laparoscopic Management in Patients With Penetrating Anterior Abdominal Wall Trauma

Summary: the current study is aiming to evaluate the diagnostic and therapeutic role of laparoscopy in patients with penetrating anterior abdominal wall trauma as regard the accuracy of diagnosis and efficacy in management and avoidance of unnecessary laparotomy


Eligibility criteria:
inclusion criteria: * all patients with penetrating anterior abdominal wall injuries age will be between 5 - 65 years old exclusion criteria: * vitally unstable patients patients with associated injuries
the effect of perineural injection therapy versus steroid in patients with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is the most common peripheral entrapment neuropathy with involving compression of the median nerve in the carpal tunnel. rather than other progressive disease, cts is characterized by remission and recurrence. although many conservative managements of cts, the effectiveness of these methods is insignificant or only persist for a short duration including steroid injection. recently, the ultrasound-guided perineural injection with 5% dextrose was widely used for entrapment neuropathy with positive benefit. the investigators design a randomized, double-blind, controlled trail to assess the effect of ultrasound-guided perineural injection with 5% dextrose in patients with cts and compared with steroid injection.

after obtaining written informed consent, patients of clinically diagnosed with cts were randomized into intervention and control group. participants in intervention group received one-session ultrasound-guided perineural injection with 5% dextrose and control group received one-session ultrasound-guided perineural injection with steroid. no additional treatment after injection through the study period. the primary outcome is visual analog scale (vas) and secondary outcomes include boston carpal tunnel syndrome questionnaire (bctq), cross-sectional area (csa) of the median nerve, sensory nerve conduction velocity of the median nerve, and finger pinch strength. the evaluation was performed pretreatment as well as on the 2nd week, 1st, 2nd, 3rd and 6 month after the treatment.

Eligibility criteria:
inclusion criteria: * age between 20-85 year-old. * diagnosis was confirmed using an electrophysiological study and ultrasonography exclusion criteria: cancer * coagulopathy * pregnancy * inflammation status * cervical radiculopathy * polyneuropathy, brachial plexopathy * thoracic outlet syndrome * previously undergone wrist surgery or steroid injection for cts

Keywords: perineural injection ultrasound-guided dextrose steroid
special drug use investigation for adoair (fluticasone/salmeterol)

Conditions: Respiratory Disorders

Summary: the purpose of this study is to detect adverse drug reactions for long-term use (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the japanese asthma patients who are treated with fluticasone propionate/salmeterol xinafoate.


Eligibility criteria:
inclusion criteria: * must use fluticasone and salmeterol for the first time * must use fluticasone and salmeterol for long-term exclusion criteria: * patients with hypersensitivity to salmeterol and fluticasone * patients with infection which salmeterol and fluticasone is not effective * patients with deep mycosis
detecting infections rapidly and easily for bacteremia trial (direbt)

Conditions: Bacteremia

Summary: to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the t2 bacteremia assay.

this protocol is intended for use by external sites collecting clinical research specimens for t2 biosystems' use in developing the t2bacterial assay. specimens and information on patients' medical history, blood properties, medications, and blood culture history/results are required from the t2bacterial assay's target patient population (i.e., candidates for blood culture). ideally, clinical specimens for use in developing the t2bacterial assay will be collected from negative blood culture, positive non-bacteria blood culture and positive bacteria blood culture patients.

Eligibility criteria:
inclusion criteria: * subject or subject's authorized representative must be able to understand, read and sign the study specific informed consent form after the nature of the study has been fully explained to them. * males and females 18 - 95 years of age. for group a, * subject is confirmed to have bacteremia (gram negative rods, gram negative coccobacillus, and/or gram positive cocci) as evidenced by a positive diagnostic blood culture * subsequent species identification identifies the presence of one of the following 6 species of bacteria: * acinetobacter baumannii * staphylococcus aureus * klebsiella pneumonia * pseudomonas aeruginosa * enterococcus faecalis * enterococcus faecium for group b, * males and females 18 - 95 years of age. * subject is confirmed to not have bacteremia from the 6 bacteria species targeted by this study, as evidenced by diagnostic blood culture and subsequent species identification. exclusion criteria: * use of any novel (i.e. not commercially available) drug compound within 30 days prior to the collection of t2 blood specimens. * subject has other co-morbid condition(s) that, in the opinion of the investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study. * subject has had an anti-bacterial drug administered through the same port or central line as is used to collect the clinical research specimens. a line draw cannot be used to obtain a study sample if an antibacterial agent was administered intravenously within the last 72 hours, unless the site can specifically document that a different line was used to administer the anti-bacterial agent.

Keywords: bacteremia sepsis acinetobacter baumannii staphylococcus aureus klebsiella pneumonia pseudomonas aeruginosa enterococcus faecalis magnetic relaxation detection nuclear magnetic resonance detection blood culture
connection, navigation, engagement in care and treatment for opioid use disorder

Conditions: Opioid-use Disorder

Summary: the overarching goal of the study is to develop, pilot, and evaluate an intervention that aims to retain patients who initiate buprenorphine at denver health in ongoing treatment for opioid use disorder.

initiating patients identified with opioid use disorder in hospital settings onto buprenorphine is a relatively new strategy to prevent overdose. while the literature is beginning to amass showing the effectiveness of this strategy for initiating people into treatment, a dearth of data to describe how well people are maintained in treatment remains. the current research project aims to 1) develop an intervention to enhance engagement and retention in treatment for individuals with opioid use disorder who initiate buprenorphine at denver health and 2) assess acceptability, feasibility, and initial efficacy of an intervention to enhance engagement and retention in treatment for individuals with opioid disorder compared to usual care.

Eligibility criteria:
inclusion criteria: * 18 years and older * inducted onto buprenorphine at denver health * successfully completed an intake visit at denver health's outpatient behavioral health services clinic. exclusion criteria: * unable to provide informed consent * unable to provide detailed contact information * previously enrolled in the current study * pregnant women will be excluded given that they are a priority treatment population and receive special services
drug-free without toothache. a study of free dental treatment as a part of substance abuse treatment

Conditions: Substance Abuse; Dental Caries

Summary: objectives: the main objective of the study is to investigate 1. how many patients will attend and complete dental care if they are offered it for free during the stay at "the department of substance abuse treatment, university hospital north norway (unn) in narvik". 2. explore whether a parallel dental treatment in addition to the other treatment at the department has a beneficial effect on the abuse treatment, or whether it can be disruptive to offer dental treatment in combination with admission for drug rehabilitation?

this is a non-randomized clinical study without a control group. approximately 50 persons admitted to "the department of substance abuse treatment (russeksjon unn narvik)" will be offered free dental service during treatment for drug addiction.

Eligibility criteria:
inclusion criteria: people who are hospitalized for drug abuse at russeksjon unn narvik. exclusion criteria: non

Keywords: non randomized interventional study
new approach for treatment of behavioral disorders in alzheimer's disease (alzheimer's behavioral and cognitive disorders)

Conditions: Alzheimer Disease; Behavioral Disorders; Cognitive Impairment

Summary: alzheimer's disease (ad) is the most frequent form of dementia, causing high level of disability with elevated social costs. alternative solutions to the standard pharmacological therapies have been studied in order to reduce the use of medications that frequently generates side effects and worsen patients' quality of life. a recent alternative treatment for ad is the environmental ecological therapy (eet) that, with the use of therapeutic gardens, seems to reduce behavioral disorders (bd). however, the effectiveness of this approach is still mater of debate. therefore, the aim of this trial will be to analyze the effects of eet, in people with severe ad.

since homo sapiens evolved in a natural environment, an intrinsic physiologic and psychological positive reaction to nature has been developed. accordingly, emerging literature highlights the positive effect of therapeutic gardens, as environmental ecological therapy (eet) on the reduction of behavioral disorders (bd) and the preservation of cognitive functions in patients with alzheimer's disease (ad). despite these promising preliminary studies, limited data are available on the effectiveness of eet in individuals with advanced ad. therefore, the aim of the current trial will be to evaluate the effectiveness of eet on ad symptoms in patients with advanced ad. participants with advanced ad will be selected from among residents of the alzheimer's care units of the mons. mazzali foundation (mantua, italy). selected participants will be randomly assigned to a treatment group (tr), or to a control group (ctrl). participants assigned to tr group will perform a program of eet for 2 hours a day, 5 days a week for a total of 6 months. individuals assigned to the ctrl group will be treated with a standard therapy.

Eligibility criteria:
inclusion criteria: * person with alzheimer's disease. exclusion criteria: * bedridden patients.

Keywords: neurological disorders non pharmacological treatment ecological therapy
kinesio-taping and chest physiotherapy program after mastectomy

Conditions: Mastectomy

Summary: the modified radical mastectomy (mrm) is a major surgical approach that necessitates the dissection of axillary lymph nodes. as a result, there is more bleeding and the treatment takes longer time. this treatment is used to treat locally advanced breast cancer. numerous factors, including pain and respiratory depression from general anaesthesia, can impair respiratory function during the post-operative period. pain causes the thoracic cage's post-operative movement to be restricted and the breathing muscles to become inhibited.

kt is a new technology that is being used in the treatment of post-surgical and respiratory problems, among other innovative evidence-based therapeutic options in patient care. recently, this method is useful for treating a variety of sports-related and musculoskeletal disorders, as well as pain management. according to a small body of research on the usefulness and efficacy of kt in treating respiratory conditions in patients with chronic obstructive pulmonary disease (copd), it can lead to improvements in respiratory muscle strength and pulmonary function.

Eligibility criteria:
inclusion criteria: * females aged between 30 and 50 years * participants after modified radical mastectomy * participants able to comprehend instructions. * cooperative participants, and willing to participate in the study. exclusion criteria: * participants having sensitive skin, scars, or lesions. * participants with unhealed incisions at the site of application. * participants with uncontrolled diabetes. * participants with deep vein thrombosis. * participants with previous chest diseases. * pregnancy. * participants with altered sensations. * participants with allodynia. * participants with active infection.

Keywords: kinesiotaping pain physiotherapy pulmonary function respiratory muscle strength quality of life
hd-tdcs for pain reduction in post-stroke pain: a randomized crossover trial

Conditions: Stroke; Pain; CPSP; TDCS

Summary: this study aims to assess the effectiveness of multichannel transcranial direct current stimulation (tdcs) in alleviating pain and to evaluate its safety in patients with central post-stroke pain (cpsp)


Eligibility criteria:
inclusion criteria : * adults aged between 19 and 90 years. * diagnosed with first-ever stroke based on clinical observation and neuroimaging by a physician. * stroke lesion located in the cortex or subcortex \[basal ganglia (bg) or thalamus\]. * fulfillment of mandatory criteria for pain (pain in the body part corresponding to central nervous system lesions, onset of pain immediately after stroke, confirmation that the pain corresponds to the lesion site, exclusion of other causes of pain such as peripheral neuropathic pain). * cognitive ability sufficient to understand and follow the instructions of the researcher. * voluntary consent to participate in the clinical trial and signed informed consent. exclusion criteria : * history of fractures or orthopedic surgeries on the affected side. * presence of significant pre-existing neurogenic disorders. * co-existing severe psychiatric disorders such as major depressive disorder, schizophrenia, bipolar disorder, or dementia. * complex regional pain syndrome (crps) diagnosed based on budapest criteria. * other causes of pain in the affected area, such as peripheral nerve damage. * exclusion criteria for transcranial magnetic stimulation (e.g., pregnancy, cancer, patients with abnormal responses to stimulation, presence of intracranial metal implants, hypersensitivity to pain, history of seizures, or injuries/skin conditions at electrode attachment sites). * deemed unsuitable for participation in the study by the principal investigator.
validation of a proteomic biomarker to predict progression of chronic kidney disease

Conditions: Chronic Kidney Disease(CKD); Progression, Disease

Summary: the goal of this longitudinal observational study is to estimate the performances of a candidate proteomic biomarker to identify patients at short term risk of chronic kidney disease (ckd) progression, in ckd patients attending nephrology visits in 3 participating centres. the primary endpoint of ckd progression is defined as a relative change in egfr observed at 1 year below -10%. the performance of the candidate biomarker will be compared to performances of uae and kfre equations. pariticipants will attend two study visits (baseline and 1-year), with clinical evaluation including kidney parameters (egfr, urinary albumin excretion (uae)) and collection of biological samples (plasma, serum, urine) for candidate proteomic biomarker evaluation. if planned in routine, patients will also have creatinine clearance estimation from 24-hour urine collection, kidney echography and kidney biopsy, sample biobanking and/or questionnaires and interviews on social and ethical aspects.


Eligibility criteria:
inclusion criteria: * male or female patients * over 18 years and below 85 years of age at recruitment * chronic kidney disease (ckd) * egfr of 25-65 ml/min/1.73m2 (ckd-epi formula) * beneficiary of health insurance * must be able to communicate with the investigator * written informed consent must be provided before participation. exclusion criteria: * history of renal transplantation * current episode of acute kidney injury * any clinically significant disorder, which in the investigator's opinion could interfere with the results of the trial. * known or suspected abuse of alcohol or narcotics * current pregnancy * inability to give written informed consent * protected adults
catequentinib in patients who have completed an advenchen study (a compassionate use trial)

Conditions: Sarcoma,Soft Tissue; Gynecologic Cancer

Summary: catequentinib (al3818, anlotinib) has been developed in a variety of clinical studies as single agents or in combination with others. this trial is designed to offer patients who completed an advenchen sponsored al3818 related study without progression the opportunity to continue to receive this investigational product in this post-trial access study (a compassionate use trial), if the investigator believes the patients can benefit from such a treatment and the patients have signed the informed consent form.

this is an open label trial and is designed to offer patients who are in a completed advenchen sponsored al3818 study without progression the opportunity to continue to receive al3818. qualified patients will continue therapy on their regimen established in the approved parent al3818 clinical study until disease progression, physician decision, patient withdrawal, or sponsor discontinuation of the study. dose modifications will be based on the suggestions in the approved parent al3818 clinical study. patients may be required to come to the site to receive al3818. for patients who cannot come to the site to receive al3818, the site may mail the drug to the patient. the exact dispersing methods will be based on the investigator's discretion.

Eligibility criteria:
inclusion criteria: * patients must be currently receiving treatment with al3818 on a previously approved parent protocol, including drug crossover patients. * patients must have achieved stable disease, partial response or complete response based on the most recent tumor assessment. if progressive disease on the most recent tumor assessment, the investigator believes the patient can clinically benefit from continuing to receive al3818. * female patients of child-bearing potential, and male partners must consent to use a medically acceptable method of contraception throughout the study period and for 4 months after the last dose of either study drug. * patient is willing and able to sign a new informed consent. * patients for whom the investigator believes can benefit from continuing to receive al3818 exclusion criteria: * patient has been discontinued from their previous al3818 trial treatment greater than 3 weeks (one cycle) prior to entering the compassionate use trial. * patient progressed while receiving therapy with al3818 during their participation in their immediate previous trial unless the investigator believes the patient can clinically benefit from continuing to receive al3818.
his bundle pacing in bradycardia and heart failure

Conditions: Bradycardia; Heart Failure

Summary: participants in this study will either have heart failure (hf) and are scheduled to undergo pace maker (pm) implantation, cardiac resynchronization therapy pacemaker (crt-p), cardiac resynchronization therapy defibrillator (crt-d) implantation, his bundle pacing (hibp) or left bundle area pacing (lbap) (including hibp/lbap for patients with hf, for patients who have failed crt implant or patients who are crt non-responders), or have atrioventricular (av) block or bradycardia and are scheduled to undergo dual chamber pacemaker implantation. in this study additional heart rhythm measurements will be collected during the implant procedure to better understand how his bundle and/or parahisian pacing (hisp) effects electrical conduction in the hearts of patients with hf or av block. the hypothesis is that his bundle or parahisian pacing (hisp) and left bundle area pacing (lbap) may normalize atrioventricular (av) conduction with a narrow combination of the q wave, r wave and s wave (qrs complex) in functional bundle branch block or conduction delay in patients with heart failure (hf).


Eligibility criteria:
inclusion criteria: hf group * clinically recommended to undergo pm, crt-p, or crt-d implantation or hibp/lbap (including hibp/lbap for patients with hf, for patients who have failed crt implant or patients who are crt non-responders) * any qrs duration * lvef ≤ 50% av block/bradycardia group * recommended to undergo dual chamber pacemaker implantation * any av block or sinus bradycardia exclusion criteria: * age \< 18 years * pregnant
extension to study hmr1964a/3011 in belgium

Conditions: Diabetes Mellitus

Summary: the purpose of this trial is to allow patients to continue on hoe 901 until launch and to gather additional long-term safety data.


Eligibility criteria:
inclusion criteria: * subjects treated with hoe901 and who, in the judgement of the investigator, have benefited from the use of hoe 901 in a previous clinical study with hoe 901. * subjects treated with hoe 901 in a previous clinical study with hoe 901 for whom a change of basal insulin would destabilise glucose metabolism. * subjects who are likely to comply with the investigator's instructions. exclusion criteria: * evidence of an uncooperative attitude. * subject not on adequate contraception, or who is pregnant, or breast feeding. * subject unable to understand informed consent. * patient receiving or likely to receive hoe901 treatment outside of spc or pi recommendations. * subject becomes pregnant or is planning to become pregnant.